Ocular Therapeutix (OCUL) Current Deferred Revenue (2013 - 2026)

Ocular Therapeutix's Current Deferred Revenue history runs 9 years deep, the most recent figure standing at $14.0 million for Q1 2026.

• On a quarterly basis, Current Deferred Revenue rose 21775.0% year-over-year to $14.0 million in Q1 2026; TTM through Mar 2026 was $14.0 million, a 21775.0% increase from a year earlier, with the FY2025 full-year figure at $14.0 million, down 0.91% from the prior year.
• Current Deferred Revenue was little changed at $14.0 million in Q1 2026 per OCUL's latest filing, from $14.0 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $14.3 million in Q1 2024 and bottomed at $64000.0 in Q1 2025.
• The 5-year median for Current Deferred Revenue is $603000.0 (2022), against an average of $5.3 million.
• Across the five-year window, Current Deferred Revenue tumbled 99.55% in 2025 and soared 21775.0% in 2026, its largest moves.
• Year by year, Current Deferred Revenue stood at $576000.0 in 2022, then plunged by 55.73% to $255000.0 in 2023, then surged by 5440.39% to $14.1 million in 2024, then decreased by 0.91% to $14.0 million in 2025, then changed by 0.0% to $14.0 million in 2026.
• Per Business Quant, the three latest OCUL Current Deferred Revenue figures stand at $14.0 million (Q1 2026), $14.0 million (Q4 2025), and $14.0 million (Q3 2025).